Merck & Co.

Novavax to provide 1.1 billon COVID-19 vaccine doses to COVAX

COVAX is the vaccine pillar of the WHO’s ACT Accelerator – a collaborative initiative co-led by Gavi, the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI)

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

AstraZeneca and Merck &Co (MSD) have revealed positive results for their PARP inhibitor Lynparza in the early, adjuvant setting for certain breast cancer patients. ... said Roy Baynes, senior vice president and head of global clinical development, chief

Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors

Companies will co-develop molecules for the treatment of immunological and neurodegenerative diseases. ... Lilly will co-develop and commercialise R552 across all indications, including autoimmune and inflammatory diseases.

Pfizer/BioNTech and Moderna increase COVID-19 vaccine supplies to the EU

We have taken additional steps to expand our manufacturing capacity to two billion doses in 2021,” said Ugur Sahin, chief executive officer and co-founder of BioNTech.

South African variant reduces antibody levels produced by Pifzer/BioNTech’s COVID-19 vaccine

Pei-Yong Shim, professor at UTMB and co-author of the study, told Reuters that he believes the Pfizer/BioNTech vaccine is still ‘likely’ to offer protection against the SA variant.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]